Cargando…

Acute Myeloid Leukemia Mutations: Therapeutic Implications

Acute Myeloid Leukemia (AML) is an extremely heterogeneous group of hematological neoplasms, for which allogeneic stem cell transplantation (HSCT) still represents the only potentially curative option in the majority of cases. However, elderly age and clinically severe comorbidities may often exclud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papayannidis, Cristina, Sartor, Chiara, Marconi, Giovanni, Fontana, Maria Chiara, Nanni, Jacopo, Cristiano, Gianluca, Parisi, Sarah, Paolini, Stefania, Curti, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600275/ https://www.ncbi.nlm.nih.gov/pubmed/31163594 http://dx.doi.org/10.3390/ijms20112721

Ejemplares similares

P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
por: Cristiano, Gianluca, et al.
Publicado: (2023)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2021)

Editorial: Precision medicine for acute myeloid leukemia
por: Marconi, Giovanni, et al.
Publicado: (2023)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)

Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
por: Ravaioli, Federico, et al.
Publicado: (2021)

The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
por: Marconi, Giovanni, et al.
Publicado: (2023)

A Case Report of Acute Myeloid Leukemia and Neurofibromatosis 1
por: Sartor, Chiara, et al.
Publicado: (2013)

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report
por: De Benedittis, Caterina, et al.
Publicado: (2017)

Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients
por: Zuffa, Elisa, et al.
Publicado: (2015)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2019)

Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters
por: Parisi, Sarah, et al.
Publicado: (2022)

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
por: Sartor, Chiara, et al.
Publicado: (2023)

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2018)

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
por: Padella, Antonella, et al.
Publicado: (2021)

PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE
por: Amato, Viviana, et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-Like Chemotherapeutic Schedule
por: Papayannidis, Cristina, et al.
Publicado: (2014)

Chromothripsis in Acute Myeloid Leukemia: biological features and impact on survival
por: Fontana, Maria Chiara, et al.
Publicado: (2017)

Chromothripsis in acute myeloid leukemia: biological features and impact on survival
por: Fontana, Maria Chiara, et al.
Publicado: (2018)

Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome
por: Sartor, Chiara, et al.
Publicado: (2013)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2019)

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022)

PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
por: Kayser, Sabine, et al.
Publicado: (2023)

Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival
por: Corradi, Giulia, et al.
Publicado: (2018)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery
por: Simonetti, Giorgia, et al.
Publicado: (2018)

Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment
por: Rizzari, Carmelo, et al.
Publicado: (2014)

P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS
por: Ocadlikova, Darina, et al.
Publicado: (2023)

Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2020)

Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy
por: Ruggeri, Loredana, et al.
Publicado: (2015)

P451: GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA.
por: Ferrari, Anna, et al.
Publicado: (2023)

CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia
por: Yakymiv, Yuliya, et al.
Publicado: (2019)

Clinical implications of recurrent gene mutations in acute myeloid leukemia
por: Yu, Jifeng, et al.
Publicado: (2020)

Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
por: Marando, Ludovica, et al.
Publicado: (2020)

Chronic myeloid leukemia stem cells: targeting therapeutic implications
por: Mojtahedi, Hanieh, et al.
Publicado: (2021)

Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism
por: Raimondo, Stefania, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uv37u4g9b0fvdrub658ihe19a0